<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03006432</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 51</org_study_id>
    <nct_id>NCT03006432</nct_id>
  </id_info>
  <brief_title>PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA</brief_title>
  <acronym>GASTFOX</acronym>
  <official_title>ESSAI DE PHASE III RANDOMISE EVALUANT LE FOLFOX AVEC OU SANS DOCETAXEL (TFOX) EN 1ère LIGNE DE CHIMIOTHERAPIE DES ADENOCARCINOMES OESO-GASTRIQUES LOCALEMENT AVANCES OU METASTATIQUES</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer is the fourth commonest cancer and the second largest cause of mortality from
      cancer. Surgical resection of localised forms of gastric cancer offers the only chance of a
      cure. The vast majority of patients, however, present with advanced disease from the outset
      (locally advanced or metastatic) or recurrent after resection of a localised form.

      For metastatic or locally advanced stages of gastric or gastro-oesophageal junction
      adenocarcinoma, the combination of 2 chemotherapy drugs (dual therapy) as compared with
      monotherapy or no chemotherapy, makes it possible to improve the tumour response and patient
      survival. Dual therapy comprising cisplatin + fluoropyrimidine (CF protocol) is considered as
      one of the first-line chemotherapy treatment standards.

      The addition of docetaxel to the CF regime (referred to as the DCF protocol) has made it
      possible to improve the tumour response rate, the time to tumour progression and overall
      survival in a randomised phase III trial. This improvement in treatment efficacy was
      achieved, however, at the expense of a significant increase in grade 3-4 toxicity, including
      diarrhoea , neutropenia, and neutropenia with complications. Although DCF is considered as a
      therapeutic standard for advanced forms of gastric cancer, its use is limited in clinical
      practice due to its high toxicity.

      Oxaliplatin has shown its usefulness in treatment of oesophagogastric cancer, with an
      efficacy at least equal to that of cisplatin. Peripheral sensory neuropathy was less common
      in the 5FU-cisplatin arm. In terms of treatment efficacy, 5FU-oxaliplatin versus
      5FU-cisplatin was associated with a non-significant improvement in median progression free
      survival rates, and overall survival.

      All these data thus suggest that 5FU-oxaliplatin is at least as efficacious and is better
      tolerated than 5FU-cisplatin, and also that docetaxel-5FU-cisplatin is more efficacious than
      5FU-cisplatin, with limited use due to its high toxicity. In the logical continuation of
      development of chemotherapy protocols for metastatic gastric cancer, the question therefore
      arises of the usefulness of adding docetaxel to 5FU-oxaliplatin, in terms of efficacy and
      also tolerance.

      In France, chemotherapy with FOLFOX is used extensively as a first line of treatment in
      advanced gastric cancer, but with progression-free survival and median survival rates that
      are still too low, and a poor response rate. The use of docetaxel at a dose of 50 mg/m2 every
      2 weeks in combination with FOLFOX (TFOX protocol) has shown very interesting results in
      phase II studies in terms of efficacy and tolerability, and these are worth confirming
      through a phase III randomised trial. In fact, if these results are confirmed in phase III,
      TFOX could become the new first-line therapeutic standard for advanced gastric cancer, while
      limiting toxicity and preserving patients' quality of life, and could become the reference
      treatment to accompany the targeted therapies currently being developed for this disease.

      The primary objective of this randomised phase III trial is to compare the progression-free
      survival on dual therapy with 5FU-oxaliplatin (FOLFOX protocol) with triple therapy with
      5FU-oxaliplatin-docetaxel (TFOX protocol) in treatment of advanced forms of gastric or
      oesophagogastric junction adenocarcinoma. The secondary objectives are overall survival, the
      tumour response rate, toxicity, quality of life and the therapeutic index, defined as the
      ratio between the median progression-free survival and the febrile neutropenia rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>12 months after laste randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival Toxicity events (adverse events) according to NCI-CTC v4.0</measure>
    <time_frame>12 months after laste randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>12 months after laste randomisation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity events according to NCI-CTC v4.0</measure>
    <time_frame>12 months after laste randomisation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">506</enrollment>
  <condition>OESOPHAGO-GASTRIC CARCINOMA</condition>
  <arm_group>
    <arm_group_label>FOLFOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cycles every 15 days until progression desease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycles every 15 days until progression desease</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>FOLFOX</arm_group_label>
    <arm_group_label>TFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5Fluorouracil bolus</intervention_name>
    <arm_group_label>FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5Fluorouracil continu</intervention_name>
    <arm_group_label>FOLFOX</arm_group_label>
    <arm_group_label>TFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>TFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <arm_group_label>FOLFOX</arm_group_label>
    <arm_group_label>TFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gastric or gastro-oesophageal junction adenocarcinoma (all Siewert), histologically
             proven (on primary tumour or metastatic lesion),

          -  HER2 negative (positive HER2 status is defined by a positive IHC test of 3+ or IHC of
             2+ with positive FISH)

          -  Metastatic or non-resectable (locally advanced) disease

          -  Disease measurable according to RECIST v1.1 criteria (at least one measurable lesion)

          -  No major surgical procedure during the 4 weeks prior to randomisation:

          -  Patient eligible for a 1st line of chemotherapy based on 5FU, folinic acid and
             oxaliplatin (FOLFOX) with or without docetaxel (TFOX)

          -  WHO: 0-1

          -  Age ≥ 18

          -  BMI &gt; 18

          -  Life expectancy &gt; 3 months

          -  PNN &gt; 1500/mm3, platelets &gt; 100,000/mm3, Hb &gt; 10 g/dL

          -  AST, ALT ≤ 3.5 times the UNL, alkaline phosphatase &lt; 6 times the UNL

          -  Bilirubin ≤ 1.5 times the UNL,

          -  Creatinine clearance according to Cockcroft and Gault formula &gt; 50 mL/min

          -  Women of childbearing age must have a negative pregnancy test (β HCG) before starting
             treatment

          -  Women of childbearing age and men (who are in a sexual relationship with women of
             childbearing age) must agree to use effective contraception without interruption for
             the duration of the treatment and for 6 months after administration of the last dose
             of treatment

          -  Patient affiliated to a social security scheme

          -  Patient information and signature of informed consent form

        Exclusion Criteria:

          -  Presence of cerebral or meningeal metastases

          -  Presence of &gt; grade 2 neuropathy according to NCIC-CTC 4.0

          -  Known DPD deficiency

          -  QT/QTc interval &gt; 450 msec for men and &gt; 470 msec for women

          -  K+ &lt; LNL, Mg2+ &lt; LNL, Ca2+ &lt; LNL

          -  Any known specific contraindication or allergy to the treatments used in the study (cf
             RCP Appendix 7)

          -  Chemotherapy or radio-chemotherapy in an adjuvant situation finished less than 12
             months ago

          -  Prior chemotherapy including oxaliplatin (except for adjuvant chemotherapy)

          -  Prior chemotherapy including docetaxel

          -  Any progressive pathology not stabilised over the past 6 months: liver impairment,
             renal impairment, respiratory or cardiac failure

          -  HIV+ patients

          -  Radiotherapy during the 4 weeks prior to randomisation

          -  Other concomitant cancer or a history of cancer during the previous 5 years, with the
             exception of carcinoma in situ of the cervix or basal cell carcinoma or epidermoid
             cell carcinoma of the skin which is considered to be cured

          -  Patient already included in another clinical trial involving an experimental drug

          -  Pregnant or breastfeeding woman

          -  Persons in custody or under wardship

          -  Impossibility of undergoing medical monitoring during the trial for geographical,
             social or psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aziz ZAANAN</last_name>
    <role>Study Chair</role>
    <affiliation>HEGP, Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie MOREAU</last_name>
    <phone>+33 (0)380393404</phone>
    <email>marie.moreau@u-bourgogne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aziz ZAANAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent HAUTEFEUILLE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franck AUDEMAR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fayçal HOCINE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Duchenne</name>
      <address>
        <city>Boulogne Sur Mer</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent BOURGEOIS</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Metropole Savoie</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier BERTHELET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samy Samy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique des Cèdres</name>
      <address>
        <city>Cornebarrieu</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain LEDIT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHI</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle COJEAN-ZELEK</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain MANFREDI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Toulon/Hyères</name>
      <address>
        <city>Hyeres</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe BERNARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Leone</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal ARTRU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Franco-Britannique</name>
      <address>
        <city>Levallois Perret</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoist CHIBEAUDEL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHM Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Belinda AIDER</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves RINALDI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Meaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence THOMAS-MARQUES</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Pierre Bérégovoy</name>
      <address>
        <city>Nevers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle ROCHE LACHAISE</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Niort</name>
      <address>
        <city>Niort</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert ALEBA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nabil BABAHAMED</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier DUBREUIL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-marc GORNET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe LOUVET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent CANY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faiza KHEMISSA</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elise DESOT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Côte Basque</name>
      <address>
        <city>Saint Jean de Luz</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Etienne MAURIAC</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Lucien Neuwirth</name>
      <address>
        <city>Saint Priest En Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Léa SABAN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse-Rangueil</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosine GUIMBAUD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé de Villeneuve d'Asq</name>
      <address>
        <city>Villeneuve D'asq</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie LEMOINE</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2016</study_first_submitted>
  <study_first_submitted_qc>December 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2016</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OESOPHAGO-GASTRIC CARCINOMA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

